Tafinlar/Mekinist (dabrafenib/trametinib)

pCPA File Number: 21132

Negotiation Status:

Concluded with an LOI

Indication(s):

Melanoma adjuvant therapy

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CADTH Project Number:

pCODR 10152

pCPA Engagement Letter Issued:

2019-06-11

Negotiation Process Concluded:

2019-08-30